Tenax Therapeutics Inc

Market Cap

$318M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$10.73-$0.32 (-2.90%)

Jun 5, 2026

52W High $18.2752W Low $5.62

Company Details

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for t...

CEO

—

IPO Date

Jan 2, 1997

Website

www.tenaxthera.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$58M

EPS (Diluted)

Free Cash Flow

-$38M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 12, 2026

FY 2025

Mar 10, 2026

Q4 2025

Mar 10, 2026

$0-100.0%

Q3 2025

Nov 12, 2025

Q2 2025

Aug 13, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee